miR-130a-3p在HCC致病机制中的作用及作为预后标志物的评估  

Role of miR-130a-3p in the Pathogenesis of HCC and Its Evaluation as a Prognostic Marker

作　　者：张凯楠 温雯 赵辉[2] 叶建蔚[3] 冉博[4] 伏建峰[5] ZHANG Kainan;WEN Wen;ZHAOHui;YE Jianwei;RAN Bo;FU Jianfeng(Graduate School,Xinjiang Medica University,Urumchi Xinjiang 830054,China)

机构地区：[1]新疆医科大学研究生学院,新疆乌鲁木齐830054 [2]新疆医科大学第一附属医院临床检验中心 [3]新疆医科大学第一附属医院肿瘤三科 [4]新疆医科大学第一附属医院肝胆包虫外科 [5]新疆军区总医院全军临床检验诊断中心

出　　处：《联勤军事医学》2023年第5期383-387,共5页Military Medicine of Joint Logistics

基　　金：新疆维吾尔自治区自然科学基金面上项目(2022D01C245)。

摘　　要：目的分析miR-130a-3p是否参与肝细胞癌(hepatocellalar carcinoma,HCC)疾病演进并抑制转移,评估其作为预后标志物的可能。方法基于癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库中miR-130a-3p的表达量和HCC患者生存信息,综合分析miR-130a-3p的表达分布以及对HCC诊断和预后价值的评估;通过抑制miR-130a-3p的表达,进而检测HepG2细胞增殖活力、细胞的迁移和侵袭能力;利用LncBase 3.0预测miR-130a-3p的靶基因,并通过Western blot检测V-maf肌骨神经纤维肉瘤肿瘤基因同源物B(V-maf musculoaponeurotic fibrosarcoma oncogene homolog B,MAFB)蛋白质表达水平,明确miR-130a-3p对MAFB的调控作用。结果miR-130a-3p在HCC组织中显著低表达(t=-13.556,P<0.001),且表达量与患者的总生存时间密切相关(Log-rank=4.675,HR=0.681,P=0.031),此外,其表达量还可以有效区分HCC患者和健康对照(AUC=0.891);抑制miR-130a-3p的表达后,HepG2细胞的增殖(t=24.950,P<0.001)、迁移(t=7.503,P=0.012)及侵袭(t=6.350,P=0.011)能力显著增强;MAFB是miR-130a-3p的靶基因之一,并且抑制miR-130a-3p后,其表达量上调(t=130,P<0.001)。结论miR-130a-3p可以作为HCC的预后评估标志物并抑制其转移。Objective To analyze whether miR-130a-3p involved in the disease evolution of hepatocellalar carcinoma(HCC)and inhibits metastasis,and to assess its potential as a prognostic marker.Methods Based on the expression level of miR-130a-3p in The Cancer Genome Atlas(TCGA)database and survival information of HCC patients,the expression distribution of miR-130a-3p and the assessment of its diagnostic and prognostic value for HCC were comprehensively analyzed;the proliferation activity,migration and invasion ability of HepG2 cells were detected by inhibiting the expression of miR-130a-3p;the target genes of miR-130a-3p were predicted by LncBase 3.0,and the expression level of V-maf musculoaponeurotic fibrosarcoma oncogene homolog B(MAFB)protein was detected by Western blot to clarify the regulatory role of miR-130a-3p on MAFB.Results miR-130a-3p was significantly under-expressed in HCC tissues(t=-13.556,P<0.001)and its expression was strongly correlated with the overall survival time of patients(Log-rank=4.675,HR=0.681,P=0.031),in addition,its expression could effectively differentiate between HCC patients and healthy controls(AUC=0.891);the proliferation(t=24.950,P<0.001),migration(t=7.503,P=0.012)and invasion(t=6.350,P=0.011)abilities of HepG2 cells were significantly enhanced after interfering with miR-130a-3p expression;MAFB was one of the target genes of miR-130a-3p and its expression was upregulated after inhibition of miR-130a-3p(t=130,P<0.001).Conclusion miR-130a-3p can be used as a marker for prognostic assessment of HCC and inhibit its metastasis.

关 键 词：肝细胞癌 miR-130a-3p V-maf肌骨神经纤维肉瘤肿瘤基因同源物B 致病机制 

分 类 号：R735.7[医药卫生—肿瘤]